

3-(N-methyl-N-n-pentylamino)-1-hydroxypropane-1, 1-diphosphonic acid, -1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid, 1-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid (risedronic acid), including N-methyl pyridinium salts thereof, for example N-methyl pyridinium iodides such as NE-10244 or NE-10446; 1-(4-chlorophenylthio) methane-1,1-diphosphonic acid (tiludronic acid), [e.g. tiludronate;] 3[N-(2-phenylthioethyl)-N-methylamino]-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-3-(pyrrolidin-1-yl)propane-1,1-diphosphonic acid, 1-(N-phenylaminothiocarbonyl)methane-1,1-diphosphonic acid, 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diphosphonic acid, and 1,1-dichloromethane-1,1-diphosphonic acid (clodronic acid).

AI
cont.


8. (Amended) A method according to claim 1, in which the bisphosphonate is pamidronic acid or zoledronic acid, or a pharmaceutically acceptable salt thereof, or any hydrate thereof.

Remarks

The claims have been amended to eliminate multiple dependencies. A marked-up version of the claims with markings to show changes made is attached hereto.

Early and favorable consideration of the application is respectfully requested.

Respectfully submitted,


Carol A. Loeschorn
Attorney for Applicants
Reg. No. 35,590

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6932

Date: November 20, 2001